Results 201 to 210 of about 690,120 (348)
New insights into mitral valve dystrophy: a Filamin-A genotype–phenotype and outcome study
T. Le Tourneau+29 more
semanticscholar +1 more source
Summary of the study design and key findings. The (+) and (−) signs mean that the variable has a positive or a negative association with growth differentiation factor‐15 (GDF‐15) levels in the fully adjusted model (age, gender, current smoker, body mass index, total cholesterol, systolic blood pressure and N‐terminal pro‐B‐type natriuretic peptide ...
Luca Monzo+11 more
wiley +1 more source
Distinguishing benign mitral valve prolapse from arrhythmic mitral valve prolapse: not always a benign entity. [PDF]
Alzahrani A, Dominic P.
europepmc +1 more source
Heterotransplantation of goat mitral valves in dogs
GEOIIGE PAPPAS+2 more
openalex +1 more source
Cardiogenic shock requiring VA‐ECMO therapy in scorpionism‐induced myocarditis
ESC Heart Failure, EarlyView.
Alba I. Violino+5 more
wiley +1 more source
Cardioprotective effects of semaglutide on isolated human ventricular myocardium
Semaglutide reduces late sodium current (INa) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end‐stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients. Improved Ca storage may underly the enhanced contractility of human cardiomyocytes upon semaglutide.
Thomas Krammer+16 more
wiley +1 more source
Rheumatic Mitral Valve Surgery: Repair or Replacement? [PDF]
Pereira LHO+10 more
europepmc +1 more source
Mitral Ball-Valve Prosthesis [PDF]
Paul Kezdi, Louis R. Head, Bruce A. Buck
openalex +1 more source
Abstract This clinical consensus statement revisits the role of left ventricular ejection fraction (LVEF) as a measurement of cardiac function, a prognostic marker and a major criterion to classify patients with heart failure, and gives new advice for clinical practice.
Giuseppe M.C. Rosano+20 more
wiley +1 more source
Applying a simplified left atrial/natriuretic peptide (LA/NP) approach by combining enlarged LA volume indexed for height2 or elevated (N‐terminal pro) B‐type natriuretic peptide [(NT‐pro)BNP], using different cut‐off values for sinus rhythm (SR) and atrial fibrillation (AF) history.
Jerremy Weerts+13 more
wiley +1 more source